Geographic atrophy
Faster GA Growth Rate Associated with BCVA Loss
Focality and foveal involvement combinations also had an impact on the rate of loss.
12/02/2024
Geographic Atrophy Appears Larger on Standard Field than UWF FAF
Optos ultra-widefield FAF is a suitable alternative to standard field FAF for longitudinal GA monitoring.
11/07/2024
Older Age, Moderate Visual Impairment Linked to Worse GA Outcomes
A study involving over 18,000 patients with the condition found that by 36 months, 19% progressed to neovascular AMD, which doubled the risk of exudative conversion in the fellow eye.
10/11/2024
Geographic Atrophy: Looking Beyond VA
A discussion on the many other markers of visual function and quality in these patients, as well as the options available to help them see better.
09/15/2024
Oral Antioxidant and Carotenoid Supplementation Slows Central GA Progression
Post hoc analysis of AREDS data clarifies the regimen’s effect in reducing lesion growth toward the fovea, a finding that could support vision preservation among patients with late-stage disease.
07/18/2024
Two Studies Give Positive Marks to Pegcetacoplan Therapy for GA
Real-world results show that the drug reduced annual growth rate by about 34%. A clinical trial extension also reported a similar level of efficacy.
05/07/2024
Similarities and Differences Between Pachychoroid GA and Conventional GA Identified
Understanding these features may help disease diagnosis in Asian populations. Patients with the former subtype were significantly younger, predominantly male and had a slower progression rate.
04/12/2024
Study Finds Imaging Biomarkers Associated with GA Growth Rate
Progression is positively associated with non-exudative subretinal fluid and hyperreflective material as well as iRORA. It’s negatively associated with retinal pseudocysts and subfoveal choroid thickness.
04/01/2024
Pachydrusen in AMD Eyes Raises Risk of MNV but Not GA
This is especially the case when macular pigmentary changes are also present, study finds.
03/20/2024
Investigative GA Drug Fares Poorly in Phase II Trial
After 24 months of treatment with oral minocycline, participants showed no significant decrease in lesion enlargement rate. Mild and moderate AEs were also common.
03/19/2024
Upcoming Events
January 14, 2025
From Comprehensive to Retina: Intelligently Advancing OCT
Location: Virtual
Presenters: Rishi P. Singh, MD, and Katherine Talcott, MD
Webinar: 8:00pm ET
Sponsored by Zeiss
May 2-3, 2025
New Technologies & Treatments in Eye Care and Intrepid Eye Society–Spring
Location: Hilton La Jolla Torrey Pines, La Jolla, California
Co-Chairs: Paul Karpecki, OD, Jake Lang, OD, and Selina McGee, OD
Earn LIVE COPE Credits* (Accreditation pending)
